[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 341
Citations 0
Correction
December 20, 2019

Language Errors in Text

JAMA Intern Med. 2020;180(2):338. doi:10.1001/jamainternmed.2019.6864

In the Letter in Reply titled “Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease—Reply,”1 published December 2, 2019, there were language errors in 2 sentences that altered meaning. The correct sentences should have read: “We agree that negative results from previous trials that included all types of patients with MCI may not be generalizable to the subset of patients with MCI who have positive results on amyloid PET.” “Even in appropriate patients with AD dementia for whom randomized clinical trials show evidence of positive treatment effects, these medications have modest benefit and may result in nontrivial harm.” This article was corrected online.

×